FUT4 and metastatic colorectal cancer: For example, FUT4 was overexpressed in most of metastatic colorectal cancer (mCRC) patients (43%), and participated in cetuximab or bevacizumab mechanisms of resistance in mCRC patients,20 which was concordant with our data FUT4 in regulating aggressiveness of SW620 and SW480 cells in vitro and in vivo.